SLC22A5 and systemic primary carnitine deficiency disease: A pharmacological carnitine deficiency animal model was established by administering the competitive OCTN2 and BBOX1 (γ butyrobetaine hydroxylase) inhibitor N-trimethyl-hydrazine-3-propionateto wild-type rats for 3 weeks.